A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

• ClinicalTrials.gov Identifier: NCT03275389
• Recruitment Status: Completed
• First Posted: September 7, 2017
• Results First Posted: May 7, 2021
• Last Update Posted: May 7, 2021
• Sponsor: GlaxoSmithKline
• Information provided by (Responsible Party): GlaxoSmithKline

Study Description

Brief Summary:

The purpose of this study is to assess the reactogenicity, safety and immunogenicity of different formulations of GlaxoSmithKline (GSK) Biologicals' investigational supra-seasonal universal influenza vaccines (SUIVs) (unadjuvanted or adjuvanted) in 18 to 39 year-old healthy subjects. Subjects will be enrolled and vaccinated with one or 2 primary dose(s) followed by a booster dose one year later.

Condition or disease	Intervention/treatment	Phase
Influenza, Human	Biological: D-SUIV cH8/1N1+AS03; Biological: D-SUIV cH5/1N1+AS03; Biological: D-SUIV cH11/1N1+AS03; Biological: D-SUIV cH8/1N1+AS01; Biological: D-SUIV cH5/1N1+AS01; Biological: D-SUIV cH11/1N1+AS01; Biological: D-SUIV cH8/1N1; Biological: D-SUIV cH5/1N1; Biological: D-SUIV cH11/1N1; Biological: Placebo; Biological: Fluarix Quadrivalent	Phase 1

Detailed Description:

Current seasonal influenza vaccines show good efficacy when they are well-matched with the circulating virus strains.

However, influenza viruses constantly change their surface glycoproteins that are the targets of most immune responses, allowing them to escape pre-existing immunity, a process called antigenic drift. Therefore, seasonal influenza vaccines have to be reformulated and re-administered on an annual basis. In addition, novel viruses can appear at irregular intervals and cause influenza virus pandemics that can claim millions of lives.

GSK Biologicals is now developing a new influenza vaccine that contains modified inactivated influenza viruses. The purpose of this approach is to elicit an immune response that would protect against all current and future circulating influenza strains without having to administer the vaccine each year.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 470 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)

Masking Description

The site staff will work in an observer-blind manner. As the vaccines appearance and preparation are different, two teams of study personnel will be set up:

• A team of unblinded personnel (responsible for the reception, preparation and administration of the vaccines).
• A team of blinded personnel (responsible for the clinical safety evaluation of the subjects).

• Primary Purpose: Prevention
• Official Title: Reactogenicity, Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults
• Actual Study Start Date: September 8, 2017
• Actual Primary Completion Date: March 26, 2020
• Actual Study Completion Date: March 26, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: D-SUIV Adjuvanted Group 1; Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.	Biological: D-SUIV cH8/1N1+AS03; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 03 (AS03) was administered intramuscularly (IM) in the deltoid region of non-dominant arm.; Biological: D-SUIV cH5/1N1+AS03; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.; Biological: Placebo; 1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
Experimental: D-SUIV Adjuvanted Group 2; Subjects received one dose of D-SUIV cH5/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.	Biological: D-SUIV cH8/1N1+AS03; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 03 (AS03) was administered intramuscularly (IM) in the deltoid region of non-dominant arm.; Biological: D-SUIV cH5/1N1+AS03; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.; Biological: Placebo; 1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
Experimental: D-SUIV Adjuvanted Group 3; Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose D-SUIV cH5/1N1+AS03 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.	Biological: D-SUIV cH8/1N1+AS03; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 03 (AS03) was administered intramuscularly (IM) in the deltoid region of non-dominant arm.; Biological: D-SUIV cH5/1N1+AS03; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.; Biological: D-SUIV cH11/1N1+AS03; 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
Experimental: D-SUIV Adjuvanted Group 4; Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.	Biological: D-SUIV cH8/1N1+AS01; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.; Biological: D-SUIV cH5/1N1+AS01; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.; Biological: Placebo; 1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
Experimental: D-SUIV Adjuvanted Group 5; Subjects received one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.	Biological: D-SUIV cH8/1N1+AS01; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.; Biological: D-SUIV cH5/1N1+AS01; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.; Biological: Placebo; 1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
Experimental: D-SUIV Adjuvanted Group 6; Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.	Biological: D-SUIV cH8/1N1+AS01; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.; Biological: D-SUIV cH5/1N1+AS01; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.; Biological: D-SUIV cH11/1N1+AS01; 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
Experimental: D-SUIV Unadjuvanted Group 1; Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.	Biological: D-SUIV cH8/1N1; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.; Biological: D-SUIV cH5/1N1; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.; Biological: Placebo; 1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
Experimental: D-SUIV Unadjuvanted Group 2; Subjects received one dose of D-SUIV cH5/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.	Biological: D-SUIV cH8/1N1; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.; Biological: D-SUIV cH5/1N1; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.; Biological: Placebo; 1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
Experimental: D-SUIV Unadjuvanted Group 3; Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of D-SUIV cH5/1N1 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.	Biological: D-SUIV cH8/1N1; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.; Biological: D-SUIV cH5/1N1; 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.; Biological: D-SUIV cH11/1N1; 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
Active Comparator: IIV4 Group; Subjects received one dose of Fluarix Quadrivalent (IIV4) vaccine at Day 1, one dose of Placebo at Day 57 and one dose of Fluarix Quadrivalent vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.	Biological: Placebo; 1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.; Biological: Fluarix Quadrivalent; 1 Primary dose and 1 Booster dose was administered IM in the deltoid region of non-dominant arm.

Outcome Measures

Primary Outcome Measures :

1. Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration [ Time Frame: During the 7-day (Days 1-7) follow-up period after first vaccine dose ]
   Assessed solicited local symptoms are pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema/swelling = erythema/swelling spreading beyond 20 millimeters (mm) of injection site.
2. Number of Subjects With Solicited Local AEs After Second Dose Administration [ Time Frame: During the 7-day (Days 1-7) follow-up period after second vaccine dose ]
   Assessed solicited local symptoms are pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema/swelling = erythema/swelling spreading beyond 20 millimeters (mm) of injection site.
3. Number of Subjects With Solicited Local AEs After Booster Dose Administration [ Time Frame: During the 7-day (Days 1-7) follow-up period after booster vaccine dose ]
   Assessed solicited local symptoms are pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema/swelling = erythema/swelling spreading beyond 20 mm of injection site.
4. Number of Subjects With Solicited General AEs After First Dose Administration [ Time Frame: During the 7-day (Days 1-7) follow-up period after first vaccine dose ]
   Assessed solicited general symptoms are arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as oral temperature equal to or above 38.0 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade
5. Number of Subjects With Solicited General AEs After Second Dose Administration [ Time Frame: During the 7-day (Days 1-7) follow-up period after second vaccine dose ]
   Assessed solicited general symptoms are arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as oral temperature equal to or above 38.0 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade
6. Number of Subjects With Solicited General AEs After Booster Dose Administration [ Time Frame: During the 7-day (Days 1-7) follow-up period after booster vaccine dose ]
   Assessed solicited general symptoms are arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as oral temperature equal to or above 38.0 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade.
7. Number of Subjects With Any Unsolicited AEs Post-vaccination Period [ Time Frame: During the 28-day (Days 1-28) follow-up period accross doses ]
   An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination
8. Number of Subjects With Change From Baseline in Hematological and Biochemical Laboratory Results at Day 8 by Toxicity Grading [ Time Frame: At Day 8 ]
   Hematological parameters assessed are: Eosinophils increase [EOSi], hemoglobin decrease [HEMd] , lymphocytes decrease [LYMd], Neutrophils decrease [NEUd], platelets decrease [PLTCd], white blood cells decrease [WBCd], WBC increase [WBCi]. Biochemical parameters assessed are: alanine aminotransferase increase [ALTi], aspartate aminotransferase increase [ASTi], blood urea nitrogen [BUN], creatinine [CRE].Toxicity grading is according to the Food and Drug Administration (FDA) guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as follows: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as follows: Parameter- grading at Baseline- grading at Timing: e.g.: "ALT-Grade 0-Grade 1".
9. Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 29 Versus Baseline by Toxicity Grading [ Time Frame: From Day 8 to Day 29 ]
   Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: "ALT-Grade 0-Grade 1". The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome.
10. Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Day 85 Versus Baseline by Toxicity Grading [ Time Frame: From Day 8 to Day 85 ]
    Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: "ALT-Grade 0-Grade 1". The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome.
11. Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 14+28 Days Versus Baseline by Toxicity Grading [ Time Frame: From Day 8 to Month 14 + 28 days ]
    Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: "ALT-Grade 0-Grade 1". The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome.
12. Number of Subjects With Change in Hematological and Biochemical Laboratory Results From Day 8 to Month 26 Versus Baseline by Toxicity Grading [ Time Frame: From Day 8 to Month 26 ]
    Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: "ALT-Grade 0-Grade 1". The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome.
13. Number of Subjects With Any Medically-attended Adverse Events (MAEs) [ Time Frame: During the entire study period (from Day 1 up to Month 26) ]
    MAEs are defined as events for which the subject receives medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.
14. Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) [ Time Frame: During the entire study period (from Day 1 up to Month 26) ]
    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
15. Number of Subjects With Serious Adverse Events (SAEs). [ Time Frame: During the entire study period (from Day 1 up to Month 26) ]
    SAEs include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
16. Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Enzyme-linked Immunosorbent Assay (ELISA)- Day 1 [ Time Frame: At Day 1 ]
    Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 ELISA.Unit per milliliter (EL.U/mL).
17. Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 29 [ Time Frame: At Day 29 ]
    Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 EL.U/mL.
18. Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Day 85 [ Time Frame: At Day 85 ]
    Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 EL.U/mL.
19. Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 1 [ Time Frame: At Day 1 ]
    Concentrations are presented as Geometric Mean Concentrations (GMCs) and measured by ELISA. ELISA cut-off = 66 EL.U/mL.
20. Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 29 [ Time Frame: At Day 29 ]
    Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 66 EL.U/mL.
21. Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Day 85 [ Time Frame: At Day 85 ]
    Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 66 EL.U/mL.
22. Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by Microneutralization (MN) Assay - Day 1 [ Time Frame: At Day 1 ]
    Anti-H1 stalk immune response measured by MN are expressed in 1/DILUTION (DIL). The functionality of the stalk-reactive antibodies is evaluated by MN assays developed using chimeric viruses. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value: MN cut-off = 20 1/DIL.
23. Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 29 [ Time Frame: At Day 29 ]
    Anti-H1 stalk immune response measured by MN are expressed in 1/DIL. The functionality of the stalk-reactive antibodies is evaluated by MN assays developed using chimeric viruses. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value: MN cut-off = 20 1/DIL.
24. Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by MN Assay - Day 85 [ Time Frame: At Day 85 ]
    Anti-H1 stalk immune response measured by MN are expressed in 1/DIL. The functionality of the stalk-reactive antibodies is evaluated by MN assays developed using chimeric viruses. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value: MN cut-off = 20 1/DIL.
25. Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 1 [ Time Frame: At Day 1 ]
    Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL.
26. Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 29 [ Time Frame: At Day 29 ]
    Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL.
27. Titers for Serum H1 Stalk Antibodies Measured by MN Assay - Day 85 [ Time Frame: At Day 85 ]
    Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL.
28. Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 [ Time Frame: At Day 29, compared to pre-vaccination at Day 1 ]
    Percentage of subjects with an equal or greater than (≥) 4-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.
29. Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 [ Time Frame: At Day 85, compared to pre-vaccination at Day 1 ]
    Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.
30. Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 [ Time Frame: At Day 29, compared to pre-vaccination at Day 1 ]
    Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay.
31. Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 [ Time Frame: At Day 85, compared to pre-vaccination at Day 1 ]
    Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay.
32. Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 [ Time Frame: At Day 29, compared to pre-vaccination at Day 1 ]
    Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.
33. Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 [ Time Frame: At Day 85, compared to pre-vaccination at Day 1 ]
    Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.
34. Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 29 [ Time Frame: At Day 29, compared to pre-vaccination at Day 1 ]
    Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay.
35. Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Titer Measured by MN Assay - Day 85 [ Time Frame: At Day 85, compared to pre-vaccination at Day 1 ]
    Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay.
36. Mean Geometric Increase (MGI) for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 29 [ Time Frame: At Day 29, compared to pre-vaccination at Day 1 ]
    MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1
37. MGI for Anti-H1 Stalk Antibody Concentration Measured by ELISA - Day 85 [ Time Frame: At Day 85, compared to pre-vaccination at Day 1 ]
    MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1
38. MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 29 [ Time Frame: At Day 29, compared to pre-vaccination at Day 1 ]
    MGI is defined as the geometric mean of the fold increase in serum HI titer post-vaccination compared to Day 1
39. MGI for Anti-H1 Stalk Antibody Titer Measured by MN Assay - Day 85 [ Time Frame: At Day 85, compared to pre-vaccination at Day 1 ]
    MGI is defined as the geometric mean of the fold increase in serum HI titer post-vaccination compared to Day 1

Secondary Outcome Measures :

1. Adjusted GMCs for Anti-H1 HA Stalk Antibody Measured by ELISA [ Time Frame: 28 days post priming dose(s) i.e. at Day 29 for 1 priming dose groups and at Day 85 for 2 priming doses groups ]
   The adjusted GMCs are presented to evaluate the adjuvant effect post-dose 1 and post-dose 2.
2. Concentrations of Serum H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 [ Time Frame: At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26. ]
   Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 66 EL.U/mL.
3. Number of Seropositive Subjects for Anti-H1 Stalk Antibodies Measured by ELISA- Month 8 to 26 [ Time Frame: At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26. ]
   Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 EL.U/mL.
4. Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. [ Time Frame: At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1 ]
   Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.
5. Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1 Stalk Antibody Concentration, Measured by ELISA - Month 8 to 26. [ Time Frame: At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1 ]
   Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.
6. MGI for Anti-H1 Stalk Antibody Measured by ELISA - Month 8 to 26 [ Time Frame: At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1 ]
   MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1
7. Concentrations of Anti-H2 and Anti-H18 Antibodies Measured by ELISA [ Time Frame: At Days 1, 29, 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26 ]
   Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 22 EL.U/mL (H2) and 43 EL.U/mL (H18).
8. Number of Seropositive Subjects for Anti-H2 and Anti-H18 Antibodies Measured by ELISA [ Time Frame: At Days 1, 29, 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26 ]
   Anti-H2 and anti-H18 immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 22 EL.U/mL (H2) and 43 EL.U/mL (H18).
9. Percentage of Subjects With a ≥ 4-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA [ Time Frame: At Day 29, at Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1 ]
   Percentage of subjects with a ≥ 4-fold increase of anti-H2 and anti-H18 antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA .
10. Percentage of Subjects With a ≥ 10-fold Increase of Anti-H2 and Anti-H18 Antibody Concentration Measured by ELISA [ Time Frame: At Day 29, at Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1 ]
    Percentage of subjects with a ≥ 10-fold increase of anti-H2 and anti-H18 antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA .
11. MGI for Anti-H2 and Anti-H18 Antibodies Concentrations Measured by ELISA [ Time Frame: At Day 29, at Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1 ]
    MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1.
12. Titers for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Anti-bodies Measured by MN Assay [ Time Frame: At Days 1, 29 and 85 ]
    Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL
13. Number of Seropositive Subjects for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Measured by MN Assay [ Time Frame: At Days 1, 29 and 85 ]
    Anti-H1N1 swine influenza and anti-IIV4-H1N1 immune response measured by MN assay. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value: cut-off = 20 1/DIL.
14. Percentage of Subjects With a ≥ 4-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay [ Time Frame: At Day 29 and Day 85, compared to Day 1 ]
    Percentage of subjects with a ≥ 4-fold increase of anti-H1N1 swine influenza and anti-IIV4-H1N1 antibody titers, from Day 1, is calculated with exact 95% CI by MN assay.
15. Percentage of Subjects With a ≥ 10-fold Increase of Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibody Titers Measured by MN Assay [ Time Frame: At Day 29 and Day 85, compared to Day 1 ]
    Percentage of subjects with a ≥ 10-fold increase of anti-H1N1 swine influenza and anti-IIV4-H1N1 antibody titers, from Day 1, is calculated with exact 95% CI by MN assay.
16. MGI for Anti-H1N1 Swine Influenza and Anti-IIV4-H1N1 Antibodies Titers Measured by MN Assay [ Time Frame: At Day 29 and at Day 85, compared to Day 1 ]
    MGI is defined as the geometric mean of the fold increase in serum HI titer post-vaccination compared to Day 1.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 39 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
• Written informed consent obtained from the subject prior to performance of any study specific procedure.
• A male or female between, and including, 18 and 39 years of age at the time of the first vaccination.
• Healthy subjects without acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as established by medical history and clinical examination before first vaccination and laboratory screening tests (the latter being only applicable for subjects enrolled in Phase I).
• Subjects with no history of influenza vaccination within 6 months prior to first study vaccination and who are willing to forego any influenza vaccination during the entire study period.

• Female subjects of childbearing potential may be enrolled in the study, if the subject:

  • Has practiced adequate contraception for 30 days prior to first vaccination, and
  • Has a negative pregnancy test on the day of vaccination, and
  • Has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series (last vaccination at Month 14).

Exclusion Criteria:

• Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before the first dose of study vaccines, or planned use during the study period.
• Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
• Chronic administration of immunosuppressants or other immune-modifying drugs during the period starting 6 months prior to the first vaccine dose. For corticosteroids, this will mean prednisone ≥ 20 mg/day, or equivalent. Inhaled and topical steroids are allowed.
• Administration of long-acting immune-modifying drugs within 6 months before first vaccination, or planned administration any time during the study period.
• Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose up to the blood sampling at Day 85 and in the period starting 30 days before booster vaccination at Month 14 up to the blood sample at Month 14 + 28 days.
• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
• Previous vaccination against influenza within the 6 months preceding the first vaccination at Visit 1 or planned use of such vaccines during the study period.
• History of vaccination with a (pre)pandemic influenza vaccine other than an H1N1pdm09 vaccine or history of laboratory-confirmed influenza infection other than seasonal or H1N1pdm09 influenza.
• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
• History of or current autoimmune disease.
• Subjects diagnosed with excessive daytime sleepiness or narcolepsy; or history of narcolepsy in a subject's parent or sibling.
• History of Guillain-Barré syndrome.
• History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines; a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine.
• Hypersensitivity to latex.

• Acute disease and/or fever at the time of enrolment.

  • Fever is defined as temperature ≥ 38.0°C / 100.4°F. The preferred location for measuring temperature in this study will be the oral cavity.
  • Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
  • For subjects with acute disease and/or fever at the time of enrolment, Visit 1 may be re-scheduled within the allowed time-window.
• Administration of immunoglobulins and/or any blood products during the period starting 3 months before the first dose of study vaccines or planned administration during the study period.
• Blood donation within 30 days before the first study blood sampling or planned blood donation within 30 days before and up to 30 days after any study blood sampling.
• Pregnant or lactating female.
• History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
• Female planning to become pregnant or planning to discontinue contraceptive precautions.

Additional criterion applicable for Phase I subjects:

• Hematological and/or biochemical parameters outside the laboratory normal ranges, unless the laboratory abnormalities are considered not clinically significant by the investigator.
• Liver enzymes (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) outside of the normal laboratory ranges.

Contacts and Locations

Locations

United States, Florida

GSK Investigational Site

South Miami, Florida, United States, 33143

United States, Kansas

GSK Investigational Site

Wichita, Kansas, United States, 67207

United States, New York

GSK Investigational Site

Rochester, New York, United States, 14609

United States, Texas

GSK Investigational Site

Austin, Texas, United States, 78705

United States, Virginia

GSK Investigational Site

Norfolk, Virginia, United States, 23502

Belgium

GSK Investigational Site

Wilrijk, Belgium, 2610

Sponsors and Collaborators

GlaxoSmithKline

Investigators

• Study Director: GSK Clinical Trials; GlaxoSmithKline

  Study Documents (Full-Text)

Documents provided by GlaxoSmithKline:

Study Protocol  [PDF] July 11, 2019

Statistical Analysis Plan  [PDF] September 12, 2019

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Folschweiller N, Vanden Abeele C, Chu L, Van Damme P, Garcia-Sastre A, Krammer F, Nachbagauer R, Palese P, Solorzano A, Bi D, David MP, Friel D, Innis BL, Koch J, Mallett CP, Rouxel RN, Salaun B, Vantomme V, Verheust C, Struyf F. Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial. Lancet Infect Dis. 2022 Jul;22(7):1062-1075. doi: 10.1016/S1473-3099(22)00024-X. Epub 2022 Apr 21. Erratum In: Lancet Infect Dis. 2022 Jun;22(6):e159.

• Responsible Party: GlaxoSmithKline
• ClinicalTrials.gov Identifier: NCT03275389
• Other Study ID Numbers: 207543; 2017-001584-20 ( EudraCT Number )
• First Posted: September 7, 2017
• Results First Posted: May 7, 2021
• Last Update Posted: May 7, 2021
• Last Verified: April 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP); Informed Consent Form (ICF); Clinical Study Report (CSR)
• Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study
• Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
• URL: https://clinicalstudydatarequest.com

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by GlaxoSmithKline:

Safety; Healthy adults; Immunogenicity; Supra-seasonal universal influenza vaccines - inactivated (SUIVs)

Additional relevant MeSH terms:

Influenza, Human; Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases